3 news items
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
SLGL
28 May 24
inhibitors as well as topical drug candidate SGT-210 under investigation for the treatment of rare hyper-keratinization disorders
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
SLGL
20 May 24
a Phase 3 clinical trial to investigate SGT-610 in approximately 140 subjects at about 40 experienced clinical centers in North America, the United
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
SLGL
16 May 24
as topical drug candidate SGT-210 under investigation for the treatment of rare hyper-keratinization disorders. For additional information
- Prev
- 1
- Next